| Biologic Therapy |
1 |
1 |
| Breast Cancer |
0 |
0.77 |
| Antineoplastic Drug |
0 |
0.69 |
| Cancer |
0 |
0.64 |
| Lung Cancer |
0 |
0.99 |
| Palliative Care |
0 |
0.61 |
| Colorectal Cancer |
0 |
0.56 |
| Noncolorectal Gastrointestinal Cancer |
0 |
0.56 |
| Advanced Cancer |
0 |
0.54 |
| Gastric Cancer |
0 |
0.49 |
| Lung |
0 |
0.47 |
| Patient Safety |
0 |
0.46 |
| Adverse Effects |
0 |
0.41 |
| Interstitial Lung Disease |
0 |
0.41 |
| Lung Fibrosis |
0 |
0.37 |
| Healthcare and Medical Technology |
0 |
0.33 |
| Clinical Research |
0 |
0.29 |
| Humanized Monoclonal Antibody |
0 |
0.28 |
| Breast |
0 |
0.12 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.07 |
| Renal Failure |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.06 |
| Corticosteroids |
0 |
0.06 |
| Impairment |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| New York |
0 |
0.06 |